Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (72)	3/17/1999 1:16:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 52153

OUT IN LEFT FIELD... An interesting post I picked up at GELX... messages.yahoo.com@m2.yahoo.com In particular "Then there's Immunex which languished for a short while in the 50's even after their arthritis drug approval before catching fire and it is now >150. I don't know about Immunex but Agouron had a lot of short players at it's nadir and a blistering negative article from "The Street.com" appeared in the low 20's which drove it to it's bottom. Anyone see any parallels here:) We of course had the negative article recently in the New England regional section of the WSJ which was totally full of misrepresentations and was obviously written with a lot of imput from the short sellers." I noted the high short interest at GELX before I came upon this post. Then I reflected how SCIO had a similar situation. On the day of the panels approval the WSJ had a clip which emphasized an analyst which labeled SCIO as " already fairly valued". Again IMO this played into a similar high short position's hands. Valuation is a funny word... Jeffrey